Autobio Diagnostics Co., Ltd.
603658
Rank in Stocks
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Share Price
$5.15
Last synced: 2026-10-22
Market Cap
$2.94B
Change (1 day)
0.97%
Change (1 year)
-5.80%
Country
CN
Trade Autobio Diagnostics Co., Ltd. (603658)
Category
Healthcare
P/E ratio for Autobio Diagnostics Co., Ltd. (603658)
P/E ratio as of October 2026 TTM: 19.88
According to Autobio Diagnostics Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.88. At the end of 2024 the company had a P/E ratio of 21.08.
P/E ratio history for Autobio Diagnostics Co., Ltd. from 2011 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 19.88 | 4.99% |
| 2025 | 18.94 | -10.16% |
| 2024 | 21.08 | -21.78% |
| 2023 | 26.95 | -12.85% |
| 2022 | 30.93 | -6.72% |
| 2021 | 33.15 | -60.22% |
| 2020 | 83.34 | 59.39% |
| 2019 | 52.29 | 52.04% |
| 2018 | 34.39 | -29.27% |
| 2017 | 48.63 | -22.80% |
| 2016 | 62.98 | 122.00% |
| 2015 | 28.37 | -25.67% |
| 2014 | 38.17 | -40.00% |
| 2013 | 63.62 | -24.24% |
| 2012 | 83.98 | -45.76% |
| 2011 | 154.83 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 35.70 | 79.54% |
US
|
|
| 38.25 | 92.36% |
US
|
|
| -294.36 | -1,580.38% |
US
|
|
| 18.69 | -6.00% |
CN
|
|
| 34.92 | 75.63% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.